Skip to main content
Figure 3 | BMC Research Notes

Figure 3

From: Bone marrow-derived progenitor cells attenuate inflammation in lipopolysaccharide-induced acute respiratory distress syndrome

Figure 3

Bone marrow-derived progenitor cells (BMDPC) attenuate inflammation. Rats treated with BMDPC showed significantly improved lung tissue using HE staining (C) compared to non-treatment group (B). Also, the expression of the proinflammatory adhesion molecules ICAM-1 (F) and VCAM-1 (I) were significantly reduced compared to the non-treatment group (E, H). A sham group served as a control group for all stainings (A, D, G). In the bronchoalveolar lavage (BAL) VEGF was significantly increased in the non-treatment group compared to the treatment and sham operation group (J). The W/D Ratio did not reveal any significant differences between the treatment and the non-treatment group, while it was significantly lower in the sham group compared to the two other groups (K); *p < 0,05 (values displayed as mean) non-treatment (LPS) versus treatment group (LPS + BMDPC).

Back to article page